Cyclacel Pharmaceuticals (CYCC) Expected to Announce Earnings on Monday

Cyclacel Pharmaceuticals (NASDAQ:CYCC) is expected to announce its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect Cyclacel Pharmaceuticals to post earnings of ($0.29) per share and revenue of $0.03 million for the quarter.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings results on Wednesday, April 2nd. The biotechnology company reported ($5.28) EPS for the quarter, missing analysts’ consensus estimates of ($4.64) by ($0.64). Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million.

Cyclacel Pharmaceuticals Price Performance

Shares of NASDAQ CYCC opened at $0.25 on Friday. Cyclacel Pharmaceuticals has a 1-year low of $0.17 and a 1-year high of $3.08. The business’s 50 day moving average is $4.32 and its two-hundred day moving average is $5.63. The stock has a market capitalization of $52.68 million, a P/E ratio of -0.03 and a beta of 0.52.

Shares of Cyclacel Pharmaceuticals are set to reverse split before the market opens on Monday, May 12th. The 1-16 reverse split was announced on Wednesday, May 7th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, May 9th.

Cyclacel Pharmaceuticals Announces Dividend

The business also recently declared a dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 29th were given a $2.40 dividend. The ex-dividend date of this dividend was Tuesday, April 29th. Cyclacel Pharmaceuticals’s dividend payout ratio is presently -4.29%.

Insiders Place Their Bets

In other news, CEO David E. Lazar sold 12,164,301 shares of the stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $0.48, for a total value of $5,838,864.48. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 68.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals in a research note on Saturday. They issued a “sell” rating on the stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.